Table 3.
Univariate analysis for predictors of discordance in onset comparing concordant onset with longer patient-reported and physician-reported symptom durations, respectively (days; negative towards longer patient-reported duration; bolded p<0.05)
| Variable | Longer patient-reported symptom | Longer MD-reported symptom | ||
| Coefficient | 95% CI | Coefficient | 95% CI | |
| Age | 0.731 | −0.741 to 2.203 | −0.076 | −0.163 to 0.011 |
| Female | −5.215 | −54.104 to 43.674 | 1.914 | −0.954 to 4.782 |
| Caucasian | 66.903 | 9.710 to 124.09 | 0.215 | −3.154 to 3.584 |
| Education>high school | 7.672 | −36.236 to 51.580 | 0.696 | −1.978 to 3.371 |
| Income >US$50 000 | 81.758 | 15.658 to 147.858 | 0.480 | −3.190 to 4.149 |
| Smoking | ||||
| Never | 10.839 | −34.052 to 55.729 | 0.890 | −1.744 to 3.523 |
| Past smoker | 28.732 | −17.007 to 74.470 | −0.030 | −2.708 to 2.687 |
| Current smoker | −65.606 | −124.150 to 7.062 | −1.464 | −4.899 to 1.971 |
| # of comorbidities | 0.234 | −11.370 to 11.839 | 0.149 | −0.533 to 0.831 |
| Fibromyalgia | −328.138 | −481.394 to 174.882 | −0.865 | −10.586 to 8.856 |
| Osteoarthritis | −107.260 | −176.206 to 38.313 | −0.099 | −4.172 to 3.975 |
| RF positive | −5.892 | −54.126 to 42.342 | 4.231 | 1.448 to 7.013 |
| ACPA positive | 3.959 | −47.743 to 55.661 | 2.503 | −0.393 to 5.398 |
| ACPA titre | −0.168 | −0.365 to 0.029 | 0.005 | −0.006 to 0.015 |
| Erosions | −32.970 | −89.189 to 23.248 | 1.047 | −2.232 to 4.326 |
| DAS28 | 5.372 | −10.357 to 21.101 | 0.066 | −0.842 to 0.974 |
| Swollen joint count | 1.654 | −2.026 to 5.334 | −0.067 | −0.283 to 0.150 |
| Tender joint count | 1.458 | −1.903 to 4.819 | −0.053 | −0.251 to 0.145 |
| HAQ | 1.666 | −29.965 to 33.296 | 0.954 | −0.904 to 2.812 |
| ESR | 0.937 | −0.139 to 2.013 | −0.006 | −0.066 to 0.054 |
| CRP | 0.406 | −0.821 to 1.633 | 0.028 | −0.043 to 0.099 |
| MD global score | −3.770 | −12.718 to 5.178 | 0.538 | 0.019 to 1.058 |
| Patient global score | −6.316 | −13.947 to 1.315 | 0.232 | −0.214 to 0.678 |
| CDAI | 0.264 | −1.333 to 1.862 | 0 | −0.093 to 0.093 |
| SDAI | 0.552 | −0.984 to 2.088 | 0.005 | −0.087 to 0.097 |
| Oral steroid | 70.722 | 22.155 to 119.288 | −1.833 | −4.658 to 0.992 |
| Parenteral steroid | 45.731 | −3.816 to 95.278 | −0.980 | −3.881 to 1.922 |
| Initial RA treatment | ||||
| MTX monotherapy | −0.346 | −50.228 to 49.536 | −1.529 | −4.472 to 1.413 |
| MTX combination | 57.614 | 12.283 to 102.944 | −0.165 | −2.806 to 2.477 |
| Other DMARDs | −85.503 | −139.369 to 25.636 | −0.853 | −2.526 to 4.232 |
| Biologic | 66.117 | −95.118 to 227.353 | −3.026 | −12.847 to 6.795 |
| None of the above | −21.597 | −87.697 to 44.503 | 2.440 | −1.504 to 6.384 |
ACPA, anticitrullinated protein antibodies; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score based on 28 joint count; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MD, medical doctor; MTX, methotrexate; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index.